Study design and patient disposition. ^aThe study design includes a third arm that includes patients with CML-AP R/I imatinib or dasatinib. No patients enrolled in this arm. ^bNilotinib was administered at a dose of 230 mg/m² twice daily (rounded to the nearest 50 mg) based on the recommended dose for adults of 400 mg twice daily, scaled to body surface area. ^cAt any time, discontinuation was allowed due to patient/investigator decision or due to unacceptable toxicities, disease progression, protocol deviations resulting in a significant risk to the patient’s safety, use of prohibited treatments, or pregnancy. ^dOne enrolled patient did not receive any study medication. ^eAt data cutoff (6 March 2019).